Found Weight Loss App: BBB Ratings, Consumer Complaints, and What Women Should Know Before Signing Up

Is Found a Legitimate Company?

Found is a real, operating telehealth company registered in the United States that connects patients with licensed clinicians who can prescribe FDA-approved and compounded weight-loss medications. The company is not a scam in the sense of taking money and delivering nothing. Clinicians on its platform hold valid state licenses, and the medications it prescribes are regulated substances.

"Legitimate" and "trustworthy" are not the same word, though. Several consumer protection data points give reason for caution, and women in particular face sex-specific risks with GLP-1 drugs that a rushed telehealth intake may underweight.

What LegitScript Certification Does and Does Not Mean

LegitScript is an independent verification body that reviews online pharmacies and telehealth prescribers for compliance with applicable laws and standards. As of January 2025, Found does not appear on LegitScript's list of certified telehealth providers. This does not mean Found is illegal. Many legitimate platforms have not pursued certification. It does mean an independent third party has not audited its prescribing practices, pharmacy sourcing, or data handling.

FDA Regulatory Standing

A search of FDA warning letters and enforcement actions does not surface a specific action against Found as of this writing. The FDA has, separately, issued broader guidance on compounded semaglutide and tirzepatide as shortage-list drugs, and that regulatory environment affects every telehealth prescriber including Found. Women should ask specifically which pharmacy fills their prescription and whether it is an FDA-registered 503B outsourcing facility or a traditional 503A compounding pharmacy, because 503B facilities face stricter quality standards.

BBB Complaint Data: What the Record Actually Shows

The Better Business Bureau profile for Found shows a history of filed complaints, the majority concentrated in two categories: billing and collection issues, and problems with a product or service. BBB complaint databases are not scientific samples. Satisfied customers rarely file. Still, recurring themes across independent complaints point to systemic process problems worth naming.

Billing and Subscription Cancellation

The single most consistent complaint category involves difficulty canceling subscriptions and unexpected charges after members believed they had canceled. Women who have left reviews on the BBB and on Trustpilot describe being charged for months after submitting cancellation requests, difficulty reaching customer support, and challenges obtaining refunds.

This pattern is not unique to Found. It mirrors complaints filed against several direct-to-consumer telehealth weight-loss companies. The Federal Trade Commission's Negative Option Rule, updated in 2024, requires that cancellation must be at least as easy as enrollment. If a company allows one-click sign-up but requires a phone call to cancel, that is a regulatory compliance concern.

Medication Access and Prior Authorization Gaps

A second cluster of complaints involves delays in receiving medication after payment, insurance prior authorization confusion, and members who paid out of pocket after being told their insurance would cover costs. GLP-1 medications carry list prices that can exceed $1,000 per month without coverage. Insurance coverage for anti-obesity medications remains uneven, and telehealth platforms that imply coverage without verifying individual plans create real financial harm.

Clinician Contact and Follow-Up

Some complaints describe difficulty reaching a clinician after the initial prescribing visit, or receiving automated messages when asking clinical questions. This is a genuine safety concern for women on GLP-1 medications, who may experience menstrual cycle changes, nausea that affects oral contraceptive absorption, or early pregnancy symptoms that could be confused with medication side effects.

A clinician contact framework for women on GLP-1 telehealth platforms should include at minimum: (1) a clear pathway to reach a licensed clinician within 24 hours for safety concerns, (2) documented protocol for pregnancy test recommendation if a period is missed, and (3) written guidance on oral contraceptive efficacy changes due to GLP-1-related vomiting and delayed gastric emptying. Found's publicly available materials do not consistently address all three.

Women-Specific Concerns With GLP-1 Telehealth

How the Menstrual Cycle Changes the GLP-1 Experience

GLP-1 receptor agonists slow gastric emptying and reduce appetite, effects that interact with hormonal fluctuations across the menstrual cycle. During the luteal phase, progesterone already slows gastrointestinal motility. Combining this with a GLP-1 agonist may intensify nausea and constipation in the two weeks before a period. A 2023 review in Obesity noted that women report higher rates of GLP-1-related gastrointestinal side effects than men across clinical trials, a sex difference that trial protocols have historically under-analyzed.

Women should tell any prescribing clinician where they are in their cycle when starting a GLP-1 medication, because dose titration timed to the follicular phase may reduce early side effects. This is the kind of individualized clinical guidance a telehealth platform with limited clinician contact time may not provide.

Perimenopause and Postmenopause: A Different Metabolic Picture

Weight gain during perimenopause is driven partly by estrogen withdrawal changing fat distribution toward visceral adiposity, not simply caloric surplus. Research published in Menopause describes how standard caloric-restriction models underperform in perimenopausal women because of metabolic rate changes driven by hormone flux.

GLP-1 agonists address the appetite and satiety side of this equation. They do not address estrogen-driven fat redistribution. A telehealth intake that does not ask about menopausal status and does not discuss whether menopausal hormone therapy might address the root cause is giving an incomplete picture. Women in perimenopause deserve a conversation about both tools, not just a prescription for one.

PCOS and Insulin Resistance

Polycystic ovary syndrome affects an estimated 8 to 13 percent of women of reproductive age, and insulin resistance is a central feature in most phenotypes. GLP-1 agonists reduce insulin resistance and have shown meaningful weight loss in women with PCOS in trials including a 2022 study in Fertility and Sterility that showed semaglutide improved both weight and menstrual regularity in women with PCOS and obesity.

Found does prescribe to women with PCOS. The concern is whether the intake process captures PCOS status, menstrual cycle history, and fertility intentions in enough detail to guide medication choice. Metformin, which Found also prescribes, has a stronger evidence base for PCOS-related insulin resistance and is preferred over GLP-1 agonists in women actively trying to conceive, because GLP-1 data in pregnancy remains limited.

Pregnancy, Lactation, and Contraception: Required Reading Before Enrolling

This section is not optional context. GLP-1 receptor agonists are contraindicated in pregnancy. The FDA label for semaglutide (Ozempic, Wegovy) states that the drug should be discontinued at least two months before a planned pregnancy. Tirzepatide carries the same contraindication. Animal studies show fetal harm at clinically relevant exposures, and human data in pregnancy is absent because pregnant women were excluded from all major trials.

What This Means for Women of Reproductive Age

Any woman who could become pregnant and is prescribed a GLP-1 agonist through Found or any other telehealth platform should be using reliable contraception. This is not a lifestyle recommendation. It is a drug-safety requirement.

GLP-1 medications also affect oral contraceptive absorption. Delayed gastric emptying reduces the rate at which the GI tract absorbs medications taken orally. A pharmacokinetic study in Clinical Pharmacokinetics found that semaglutide slowed gastric emptying in a dose-dependent manner, with the strongest effect in the first four weeks of use. During this window, oral contraceptive pill absorption may be reduced, and backup contraception such as condoms is advisable.

Women who vomit within two hours of taking an oral contraceptive pill should treat that pill as missed per standard missed-dose protocols. Telehealth platforms prescribing GLP-1 medications alongside or to women using oral contraceptives should provide this guidance in writing. Ask for it explicitly if Found does not offer it proactively.

Lactation

Semaglutide and tirzepatide have not been studied in breastfeeding women. The FDA label for Wegovy advises against use during breastfeeding because of the potential for serious adverse reactions in nursing infants and because animal data shows excretion in milk. Found should not be prescribing GLP-1 agonists to breastfeeding women. If a clinician on this or any platform prescribes one without asking about breastfeeding status, that is a red flag requiring immediate escalation to your own primary care provider.

Bupropion-Naltrexone (Contrave)

Found also prescribes bupropion-naltrexone combination therapy. Naltrexone is classified FDA Pregnancy Category C, and bupropion has a complex pregnancy safety profile with some studies associating first-trimester exposure with congenital cardiac defects at higher doses, though ACOG notes the data is inconsistent. Both drugs transfer into breast milk. Contrave is not appropriate in pregnancy or while breastfeeding.

Who Found May Be Right For, and Who Should Look Elsewhere

Potentially Appropriate

Women who are overweight or have obesity (BMI 27 or above with a weight-related condition, or BMI 30 or above), are not pregnant and not planning pregnancy in the near term, have already tried dietary and behavioral approaches without sustained success, want access to a prescribing clinician without an in-person visit, and live in a state where Found operates may find the platform a reasonable starting point.

Women with PCOS who have insulin resistance and are not trying to conceive are a reasonable clinical fit if the intake properly captures their history.

Perimenopausal women with significant metabolic weight gain may get some benefit from GLP-1 therapy, but they should specifically ask whether the clinician will also discuss menopausal hormone therapy, because addressing estrogen withdrawal is a complementary strategy the medication alone does not cover.

Not the Right Fit

Women who are pregnant, breastfeeding, or actively trying to conceive should not be using GLP-1 agonists and should not enroll in Found for this purpose. Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated for GLP-1 agonists per FDA labeling regardless of platform.

Women with a history of eating disorders, particularly restrictive eating disorders, should approach any telehealth weight-loss platform with caution. ACOG's guidance on obesity in pregnancy and the Obesity Medicine Association's clinical practice guidelines both emphasize individualized care that includes mental health screening, a step that a brief telehealth intake may not adequately perform.

Women who need close monitoring because of complex comorbidities such as heart failure, advanced kidney disease, or active gastrointestinal conditions including gastroparesis should work with a specialist rather than a telehealth platform with limited follow-up infrastructure.

How Found Compares to Other Telehealth Prescribers on Key Transparency Metrics

This is not a ranked comparison. It is a list of specific questions you can ask Found and any competitor to evaluate relative transparency.

Pharmacy sourcing. Ask whether your medication comes from a 503A or 503B facility if it is compounded. FDA guidance distinguishes these categories, and 503B carries higher quality-control requirements.

Clinician credentials. Ask whether your assigned clinician is a physician, nurse practitioner, or physician assistant, what their specialty training is, and whether they are licensed in your state.

Cancellation policy in writing. Request the cancellation policy before you enter payment details. Found's policy has been a source of BBB complaints; having it in writing before enrollment gives you documentation if a dispute arises.

GLP-1 shortage disclosure. Semaglutide and tirzepatide have been on FDA drug shortage lists. Ask whether Found's supply is from compounded sources and, if so, from which facility.

Women's health intake depth. Ask directly whether the intake form covers menstrual cycle history, PCOS status, perimenopausal symptoms, current contraception, and breastfeeding status. If it does not, consider whether you want to supplement with your own gynecologist or primary care provider.

Evidence Gaps Women Should Know About

Women have been consistently under-represented in obesity pharmacotherapy trials. The landmark STEP 1 trial of semaglutide enrolled approximately 74 percent women, which is better than many drug trials, but subgroup analyses by menopausal status, PCOS status, and hormonal contraceptive use were not the primary design focus and are limited. The SURMOUNT-1 trial of tirzepatide similarly enrolled a majority of women but did not stratify primary outcomes by reproductive stage.

This means the dose-response curves, side-effect profiles, and long-term weight maintenance data that telehealth platforms use to counsel patients are largely derived from pooled populations where hormonal status is not a primary variable. When a clinician at any telehealth platform tells you what to expect, some of that guidance is extrapolated from data that did not specifically study women at your life stage.

Acknowledging this gap is not a reason to avoid these medications if you meet criteria. It is a reason to stay in close contact with a clinician who will adjust based on your individual response rather than a population average.

Practical Steps Before You Enroll in Found

Get your own baseline labs first. A lipid panel, fasting glucose or HbA1c, TSH, and a complete metabolic panel give you data to track against and may surface conditions such as hypothyroidism that cause weight gain independently. Thyroid dysfunction is significantly more common in women and can mimic or worsen obesity-pattern weight gain. Starting a GLP-1 without ruling out thyroid disease means potentially treating the wrong problem.

Tell your primary care provider or gynecologist you are enrolling. Telehealth platforms operate in silos. Medication interactions, monitoring needs, and pregnancy planning decisions require a clinician who knows your full history.

Read the cancellation policy before entering payment. Screenshot or save a PDF copy of the policy at time of enrollment. If you are charged after canceling, the FTC complaint portal and your state attorney general's consumer protection office are both avenues for dispute.

Ask for a written summary of your prescribing clinician's clinical reasoning at your first visit, including why this medication at this dose was chosen for you specifically. A platform that cannot provide that is not providing individualized clinical care.